Targeting GLI Transcription Factors in Cancer
AbstractAberrant activation of hedgehog (Hh) signaling has been observed in a wide variety of tumors and accounts for more than 25% of human cancer deaths. Inhibitors targeting the Hh signal transducer Smoothened (SMO) are widely used and display a good initial efficacy in patients suffering from basal cell carcinoma (BCC); however, a large number of patients relapse. Though SMO mutations may explain acquired therapy resistance, a growing body of evidence suggests that the non-canonical, SMO-independent activation of the Hh pathway in BCC patients can also account for this adverse effect. In this review, we highlight the importance of glioma-associated oncogene (GLI) transcription factors (the main downstream effectors of the canonical and the non-canonical Hh cascade) and their putative role in the regulation of multiple oncogenic signaling pathways. Moreover, we discuss the contribution of the Hh signaling to malignant transformation and propose GLIs as central hubs in tumor signaling networks and thus attractive molecular targets in anti-cancer therapies. View Full-Text
Share & Cite This Article
Didiasova, M.; Schaefer, L.; Wygrecka, M. Targeting GLI Transcription Factors in Cancer. Molecules 2018, 23, 1003.
Didiasova M, Schaefer L, Wygrecka M. Targeting GLI Transcription Factors in Cancer. Molecules. 2018; 23(5):1003.Chicago/Turabian Style
Didiasova, Miroslava; Schaefer, Liliana; Wygrecka, Malgorzata. 2018. "Targeting GLI Transcription Factors in Cancer." Molecules 23, no. 5: 1003.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.